NCT03999710View on ClinicalTrials.gov

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Non Small Cell Lung CancerLung CancerNsclcNSCLC Stage IINSCLC, Stage III
Interventions
RADIATION

Radiation Therapy

Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.

DRUG

Durvalumab

A dose of 1500mg (for patients \>30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Commack, Commack

18103

Lehigh Valley Health Network, Allentown

33143

Baptist Alliance Miami Cancer Institute, Miami

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER